Laurion Capital Management LP Crinetics Pharmaceuticals, Inc. Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$42.12 - $51.91 $11.8 Million - $14.5 Million	-279,416 Reduced 44.34%	350,766 $15.7 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $2.13 Million - $2.86 Million	61,200 Added 10.76%	630,182 $29.5 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $14.6 Million - $21.1 Million	568,982 New	568,982 $20.2 Million
Q2 2022 Aug 15, 2022	SELL	$16.49 - $27.64 $1.32 Million - $2.21 Million	-79,952 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $1.37 Million - $2.26 Million	79,952 New	79,952 $1.76 Million
Q4 2018 Feb 14, 2019	SELL	$22.4 - $35.39 $2.64 Million - $4.17 Million	-117,700 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$22.66 - $36.8 $2.67 Million - $4.33 Million	117,700 New	117,700 $3.37 Million

241

80M

23.3K

44.3K

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.12B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.